Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab with Induction Chemo and Chemoradiation for Head and Neck Cancer
NCT00089297Phase 2Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Jan 2005
- Primary completion
- Feb 2010
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of KL-140 in head and neck squamous cell carcinoma (HNSCC), sponsored by Eastern Cooperative Oncology Group. Primary endpoint: Event-Free Survival Rate at 1 year. Started Jan 2005; status: completed.
02
Drugs
KL-140
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00089297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00089297.